FILGRASTIM
Multiple Sclerosis, Relapsing-Remitting
Northwestern Universityprotein_peptidePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.
View all 50 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →